Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
about
Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome.Management of primary Sjögren's syndrome: recent developments and new classification criteria.Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease.
P2860
Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Interleukin (IL)-17-producing ...... ren's syndrome: a pilot study.
@en
type
label
Interleukin (IL)-17-producing ...... ren's syndrome: a pilot study.
@en
prefLabel
Interleukin (IL)-17-producing ...... ren's syndrome: a pilot study.
@en
P2093
P2860
P50
P356
P1476
Interleukin (IL)-17-producing ...... ren's syndrome: a pilot study.
@en
P2093
P2860
P304
P356
10.1111/CEI.12771
P577
2016-03-03T00:00:00Z